Location:homepage  News  Research News

Research News

Professor Zhang Can 's group published an article in Nature Nanotechnology
Submission:张灿课题组  Date:2017-06-21   Page View:122

An article from Professor Zhang Can's group titled as Neutrophil-mediated anticancer drug delivery  for suppression of postoperative malignant glioma recurrence was published on Nature Nanotechnology on June 19 in 2017 (Volume 12 No 7, Page   692-700; doi:10.1038/nnano.2017.54, IF 38.986).

This paper was based on the postoperative chemotherapy of glioma. Glioma is the most common malignant invasive-growing tumor in the skull, with high mortality, high recurrence rate and low cure rate. Surgery and chemotherapy are often combined in clinical treatment. The first-line chemotherapy drug for brain glioma is timorazolamide which can cross the blood-brain barrier. Although the postoperative efficacy with timorazolamide is higher than radiotherapy, the five-year survival rate was only 9.8%. Other effective anti-tumor drugs such as paclitaxel, which can’t penetrate the blood-brain barrier, fail to be applied in clinical trials. In order to keep drugs efficiently concentrated in postoperative residual tumor, Professor Zhang’s group developed the autologous neutrophils as vectors which carry antitumor drug paclitaxel-loaded liposomes. After injected intravenously to the postoperative orthotopic glioma in mice model, the neutrophils crossed the blood-brain barrier through deformation under the tropism to inflammatory factors, thus implemented the effective independent targeted drug delivery, restraining the orthotopic glioma postoperative recurrence and development in mice.

The research based on specific diseases and their pathological factors, broke the limitation of the traditional   receptor-ligand binding design. The result set up new technology platform for   drugs crossing the blood-brain barrier and brain diseases treatment. It was expected to be applied for the treatment of inflammation and related diseases.

It took us 5 years and 3 months to overcome all difficulties and persist in exploring the idea. The paper was funded by China   National Natural Science Foundation and the Open Project Program of State Key   Laboratory of Natural Medicines, China Pharmaceutical University. The paper   was also supported by Jiangsu Key Laboratory of Drug Discovery in Metabolic   Disease.

The first author of the paper is Xue Jingwei, the 2014th   Ph.D majored in chemical medicine. The corresponding author is Prof. Zhang Can, and   the co-corresponding author is Prof. Mo Ran. The second and other main authors   are followed by: Zhao Zekai,2017th Ph.D in pharmacy, 2015th   Master Zhang Lei in pharmacy, Dr. Xue Lingjing, 2016th Master Shen   Siyang and Wei Zhuoyuan in pharmacy, 2017th Master Wen Yajing in   pharmacy, 2013th Master Wang Lu in chemical medicine,etc. Many   “unsigned authors” in our group, including Su Zhigui, Ju CaoYun, Wang Cong,   Zhang Yong, Hou Siyuan, Tang Chunming, Kang Zisheng, Zhang Yidi, Dai Lili,   Zhang Yan, Zhou Anwei and Xie Daping, contributed a lot for many supplementary experiments.

 Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence.pdf